Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.